1–3 g/day.
Reviews find no real benefit.
Doubtful benefit versus placebo.
Does not reliably improve hot flashes.
⏱ 3 min read
Evening primrose oil is the oil extracted from the seeds of Oenothera biennis, a plant native to North America and naturalized in Europe, whose main nutritional distinction is that it is one of the most concentrated dietary sources of gamma-linolenic acid (GLA), an omega-6 fatty acid that under normal conditions the body synthesizes from dietary linoleic acid via the enzyme delta-6-desaturase; when this enzyme functions suboptimally (due to age, diabetes, alcoholism, nutritional deficiencies, or genetic predisposition), exogenous GLA intake may have clinical effects on the cascade of anti-inflammatory prostaglandins derived from dihomo-gamma-linolenic acid (DGLA).
Clinical interest in evening primrose oil grew enormously in the 1980s and 1990s with publications suggesting efficacy in cyclic mastalgia, premenstrual syndrome, atopic eczema, rheumatoid arthritis, and diabetic neuropathy; the following decades of more rigorous clinical trials have considerably qualified those initial expectations, showing a general pattern of modest, heterogeneous, and often non-replicable effects, with a few specific indications where there is reasonable support.
The indication with the most widespread clinical use is premenstrual cyclic mastalgia: several small trials and European gynecological clinical practice have documented symptomatic improvements with doses of 1,500-3,000 milligrams per day (providing 130-260 milligrams of GLA) for 3-6 menstrual cycles; more recent meta-analyses have shown modest and heterogeneous effects, positioning evening primrose oil as a first-line option because of its good tolerability profile but with more conservative expectations than the initial ones.
In premenstrual syndrome with an affective or fluid-retention component, the data are inconsistent: some small trials show significant improvements while others find no benefit over placebo; the predominant current clinical opinion is that the effect, if it exists, is marginal and does not justify evening primrose oil as a first-line treatment, although it may have a place in multimodal strategies with vitamin B6, magnesium, and other nutritional interventions.
In atopic eczema, the clinical data are particularly disappointing: the Cochrane meta-analysis published in 2013 with 27 clinical trials concluded that evening primrose oil does not significantly improve atopic eczema symptoms compared with placebo, a conclusion that contradicted initial expectations and has led to it being discouraged as a standard treatment in dermatology guidelines; some patients report subjective improvements, but the aggregate evidence does not support the indication.
In rheumatoid arthritis, several small trials have shown modest improvements in morning stiffness and joint tenderness with doses of 6-11 grams per day (providing 540-980 milligrams of GLA) for 6-12 months, with a tolerability profile more favorable than that of conventional anti-inflammatories; the doses required are very high (much higher than those usual in commercial supplements) and the effects modest, which limits practical usefulness.
In diabetic neuropathy, two small trials showed significant improvements on neurological scales and in nerve conduction velocity with doses of 360-480 milligrams per day of GLA for 6-12 months; the data are interesting but have not been replicated in larger studies, and the indication has not entered standard clinical guidelines.
The doses studied vary by indication: for mastalgia and PMS, 1,500-3,000 mg/day of oil (130-260 mg of GLA); for rheumatoid arthritis, 6-11 g/day of oil (540-980 mg of GLA); for diabetic neuropathy, doses adjusted to provide 360-480 mg of GLA; typical commercial products contain 500-1,000 mg of oil per capsule with 8-10 percent GLA, so therapeutic doses require multiple capsules per day.
Generally well tolerated; the adverse effects described are rare and mild (digestive discomfort, headache, occasionally oil-flavored burping); people with epilepsy or those taking drugs that lower the seizure threshold (some antidepressants, phenothiazines) should be cautious because of preliminary data suggesting an increased seizure risk at high doses; those taking anticoagulants should take theoretical caution because of a mild antiplatelet effect; evening primrose oil is very susceptible to oxidation and should be stored refrigerated in opaque containers; in pregnancy and breastfeeding it has traditionally been used without significant problems, but consulting a clinician first is advisable; cheap products are often oxidized and therapeutically less effective, an important consideration for an intervention that already has modest effect sizes.
Information, not medical advice. Scientific evidence reflects the quality of the studies.